Im ready for the next ride:
Elites destiny can not be denied:
--8 FDA approved drugs, 7 launched
--4 quarters of rising revenues
--Lodrane 24 and 24D returning
--Lodrane D OTC gaining market share
--cash flow positive probably this quarter
--CEO loaned the co. 1 million dollars unsecured (non-dilutive)
--interest paid in full on loans
--ELI-216 ART opiods still a priority, closer along than people think
--2nd patent for ELI-216(week of April, 21 2013) giving Elite a hammerlock on superior 2 bead ART
--Patent pending approval 12/640,344 ART
--Patent pending 13/379,486 microtablet 0.25-1.0mm for all medicines
--Patent pending 13/379,481 microtablets for ART
--partner for ELI-216 could be announced any day
--Novel net worth growing, 31 FDA approved drugs including generic morning after pill
--10% ownership in Novel Labs, Novel has approached Elite for monetization
--estimates for 10% value of Novel range from 10 million to 50 million
--Elites 3.5 million debt will be eliminated with sale of Novel
--current launched drugs continue to gain market share
-- phentermine 15/30mg launched (April 11, 2013)
--BE and PK studies progressing, some near completion
--New Jersey(NJEDA) tax credits approaching 1 million dollars/yr
--Phase III trials for AR CR OXY could begin tomorrow
--impressive billion dollar pipeline
--multiple partners supporting Elite esp. Activas
--contracting deals
--NEW Packaging line operational
--2 fda approved opiod manufacturing facilities, space doubled this past year
-- 26 employees up from 16, 2 years ago
--Hong Kong NDA progressing
--MIK-001 probably an improved Embeda
--HITK's 100 million dollar branded intermediate
--first of 8 Epic drugs due out anytime
--Tagi
--505-2b's for approved generics
--STOPP ACT will benifit Elite
--Phendimetrazine ANDA
--Naltrexone FDA approved, launch pending (May-June 2013)
--undisclosed ANDA's could come out any day
--micro capsule patent progressing, smallest size in the industry, wide application, can be use on nearly any drug
--JT's goal is to have a complete line of abuse resistant opiods
--Modular Technology good for ALL opiods
--Relisting on NASDAQ 2-4 years
